Vaxcyte (Vaxcyte) FCF Yield % : -6.80 (As of May. 12, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Vaxcyte's Trailing 12-Month Free Cash Flow is $-482.56 Mil, and Market Cap is $7,092.36 Mil. Therefore, Vaxcyte's FCF Yield % for today is -6.80%.

The historical rank and industry rank for Vaxcyte's FCF Yield % or its related term are showing as below:

PCVX' s FCF Yield % Range Over the Past 10 Years
Min: -6.85 Med: 0 Max: 0
Current: -6.8

PCVX's FCF Yield % is ranked better than
64.78% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs PCVX: -6.80

Vaxcyte's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

Vaxcyte FCF Yield % Historical Data

The historical data trend for Vaxcyte's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte FCF Yield % Chart

Vaxcyte Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-3.52

-10.14

-4.63

-6.09

Vaxcyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-7.05	-5.17	-5.35	-12.41	-9.22

Competitive Comparison of Vaxcyte's FCF Yield %

For the Biotechnology subindustry, Vaxcyte's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxcyte's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Vaxcyte's FCF Yield % falls into.

Vaxcyte FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Vaxcyte's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-364.667	/	5988.90944
	=	-6.09%

Vaxcyte's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-171.196	*	4	/	7429.12236
	=	-9.22%

Vaxcyte FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Vaxcyte FCF Yield % Related Terms

Thank you for viewing the detailed overview of Vaxcyte's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcyte (Vaxcyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

5VA:Germany

Address

825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070

Website

https://www.vaxcyte.com

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

Executives

Andrew Guggenhime	officer: CFO, CBO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Grant Pickering	director, officer: President & CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman	officer: SVP, Gen Counsel & Corp Sec	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jim Wassil	officer: Chief Operating Officer	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
Elvia Cowan	officer: See Remarks Section	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jeff Fairman	officer: VP, Research	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer	officer: SVP Process Dev, Manufacturing	C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck	director	C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal	officer: SVP Cml Mfg & Supply Chain	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau	director	C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Teri Loxam	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Jane Wright Mitchell	officer: General Counsel	C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Robert Lorne Hopfner	director	C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111